Shudhanshu Alishetti, MD
Advanced Heart Failure and Transplant Cardiology · Brooklyn, NYNPI 1821431040
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $9,933 of the $12,606 with a category attached, or 78.8%. 21 manufacturers reported payments, led by Abbott at 32.5% of the total.
Across 192 payments — averaging $65.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$4K
- Alnylam Pharmaceuticals Inc.$2K
- Abiomed$2K
- Medtronic$790
- AstraZeneca$514
- Amgen$441
- plus $3K from 15 others
Across 2 payments — averaging $6285.78 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- E.r. Squibb & Sons, L.L.C.$13K
What the payments were for
- Consulting fees$1,1909%
- Travel & lodging$1,48312%
- Food & beverage$9,93379%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 43 | $4,095 |
| Alnylam Pharmaceuticals Inc. | 18 | $2,136 |
| Abiomed | 15 | $1,815 |
| Medtronic(2 entities) | 10 | $790 |
| AstraZeneca | 15 | $514 |
| Amgen | 15 | $441 |
| Kestra Medical Technology Services, Inc. | 4 | $396 |
| Ancora Heart, Inc. | 1 | $388 |
| Bridgebio Pharma, Inc. | 12 | $346 |
| Boston Scientific | 8 | $344 |
| Boehringer Ingelheim | 14 | $274 |
| Pfizer | 11 | $222 |
| Cvrx, Inc. | 1 | $192 |
| Novartis | 7 | $164 |
| E.r. Squibb & Sons, L.L.C. | 7 | $132 |
| Sanofi-aventis U.S. LLC | 5 | $112 |
| Edwards Lifesciences | 1 | $89 |
| Regeneron Healthcare Solutions, Inc. | 2 | $54 |
| Scpharmaceuticals Inc. | 1 | $50 |
| Daiichi Sankyo Inc. | 1 | $30 |
| Baxter Healthcare | 1 | $22 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Impella$1,452
- AMVUTTRA$1,437
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$1,048
- CardioMEMS HF System$809
- CARDIOMEMS$494
- HeartMate 3 Left Ventricular Assist Device$433
- AccuCinch$388
- Assure WCD$312
- ONPATTRO$258
- Barostim Neo System$192
- MitraClip System$153
- Quadra Allure MP RF CRT Pacemkr$143
- Watchman$135
- Attruby$125
- MitraClip$116
- LUX-Dx Insertable Cardiac Monitor$107
How this compares
$12,606 in reported general payments places this provider in the 70th percentile of 106 advanced heart failure and transplant cardiology providers in New York.
See all advanced heart failure and transplant cardiology providers in New York →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VyndamaxTafamidis | 102 | $3,644,408 |
| EntrestoSacubitril/Valsartan | 61 | $83,131 |
| EliquisApixaban | 39 | $48,692 |
| JardianceEmpagliflozin | 35 | $39,007 |
| FarxigaDapagliflozin Propanediol | 13 | $15,118 |
| Eplerenone | 15 | $1,412 |
| Bumetanide | 30 | $1,201 |
| Metoprolol Succinate | 51 | $837 |
| Torsemide | 19 | $671 |
| Atorvastatin Calcium | 32 | $237 |
| Omeprazole | 13 | $204 |
| Spironolactone | 25 | $167 |
| Carvedilol | 21 | $150 |
| Rosuvastatin Calcium | 16 | $132 |
| Amlodipine Besylate | 20 | $84 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerVyndamax, Eliquis | $222 | $3,693,099141 claims |
| NovartisEntresto | $164 | $83,13161 claims |
| Boehringer IngelheimJardiance | $274 | $39,00735 claims |
| AstraZenecaFarxiga | $514 | $15,11813 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 106 advanced heart failure and transplant cardiology providers in New York.
Other advanced heart failure and transplant cardiology in Brooklyn
- Norbert MoskovitsBrooklyn$159K
- Steven SorciBrooklyn$36K
- Laurie LetarteBrooklyn$20K
- Johanna ContrerasNew York$534K
- Scott FeitellRochester$422K
- Sean PinneyNew York$305K
- Mathew MaurerNew York$249K
- Gregg LanierHawthorne$239K
- Michelle BloomMineola$166K
- Stephen PanValhalla$159K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.